MedPath

Dexamethasone

Generic Name
Dexamethasone
Brand Names
Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
Drug Type
Small Molecule
Chemical Formula
C22H29FO5
CAS Number
50-02-2
Unique Ingredient Identifier
7S5I7G3JQL
Background

Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication

Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
Associated Therapies
-
Clinical Trials
Related News

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Daratumumab
Drug: Pomalidomide
Drug: All-trans retinoic acid
Drug: Dexamethasone
First Posted Date
2021-01-07
Last Posted Date
2024-01-10
Lead Sponsor
Hackensack Meridian Health
Target Recruit Count
1
Registration Number
NCT04700176
Locations
🇺🇸

John Theurer Cancer Center, Hackensack, New Jersey, United States

Peri-neural Dexmedetomidine Versus Dexamethasone for Supraaclavicular Block Adjuvant to Bupivacaine Supraclavicular Brachial Plexus Block

Not Applicable
Completed
Conditions
Brachial Plexus Block
Interventions
Drug: Dexmedetomidine injection
Drug: saline
Drug: Dexamethasone
First Posted Date
2021-01-05
Last Posted Date
2021-01-05
Lead Sponsor
Cairo University
Target Recruit Count
42
Registration Number
NCT04694105
Locations
🇪🇬

Kasr Alini Univeristy Hospital, Cairo, Giza, Egypt

The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.

Not Applicable
Completed
Conditions
Anesthesia, Local
Analgesia
Arthropathy of Hip
Interventions
Other: Opioid and non opioid postoperative analgesia.
Other: Fascia iliaca compartment block
Drug: Dexamethasone
First Posted Date
2020-12-31
Last Posted Date
2020-12-31
Lead Sponsor
Saint Lucas Hospital, Poland
Target Recruit Count
150
Registration Number
NCT04690647
Locations
🇵🇱

Saint Lucas Hospital, Konskie, Swietokrzyskie, Poland

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Phase 1
Active, not recruiting
Conditions
Recurrent Acute Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Hairy Cell Leukemia
Refractory Hematologic Malignancy
Refractory Hodgkin Lymphoma
Refractory T Acute Lymphoblastic Leukemia
Systemic Mastocytosis
Interventions
Drug: Acetaminophen
Drug: Dexamethasone
Drug: Diphenhydramine
Biological: Flotetuzumab
Drug: Ibuprofen
Drug: Ranitidine
First Posted Date
2020-12-23
Last Posted Date
2024-12-31
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
13
Registration Number
NCT04681105
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Daratumumab
Drug: Cyclophosphamide
Drug: Pomalidomide
Drug: Dexamethasone
First Posted Date
2020-12-16
Last Posted Date
2023-11-27
Lead Sponsor
Cancer Trials Ireland
Target Recruit Count
20
Registration Number
NCT04667663
Locations
🇮🇪

Beaumont Hospital, Dublin, Ireland

🇮🇪

Galway University Hospital, Galway, Ireland

🇮🇪

Cork University Hospital, Cork, Ireland

Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19

Phase 4
Completed
Conditions
Covid19
ARDS
Interventions
Drug: Dexamethasone
First Posted Date
2020-12-11
Last Posted Date
2023-03-22
Lead Sponsor
Brno University Hospital
Target Recruit Count
235
Registration Number
NCT04663555
Locations
🇨🇿

University Hospital Brno, Brno, Czechia

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

First Posted Date
2020-12-10
Last Posted Date
2024-01-05
Lead Sponsor
Hackensack Meridian Health
Target Recruit Count
96
Registration Number
NCT04661137
Locations
🇺🇸

John Theurer Cancer Center, Hackensack, New Jersey, United States

🇺🇸

Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Dexamethasone for Post Uterine Artery Embolization Pain

Phase 3
Active, not recruiting
Conditions
Leiomyoma
Interventions
Drug: Saline
Drug: Dexamethasone
First Posted Date
2020-12-07
Last Posted Date
2024-01-30
Lead Sponsor
University of Miami
Target Recruit Count
82
Registration Number
NCT04655144
Locations
🇺🇸

Sylvester Comprehensive Cancer Center, Miami, Florida, United States

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Phase 2
Recruiting
Conditions
Multiple Myeloma
Autologous Stem Cell Transplant
Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
Drug: Isatuximab
Drug: Lenalidomide
Drug: Bortezomib Injection
Drug: Dexamethasone
First Posted Date
2020-12-04
Last Posted Date
2024-11-12
Lead Sponsor
Jacob Laubach, MD
Target Recruit Count
52
Registration Number
NCT04653246
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Phase 3
Terminated
Conditions
Relapsed Multiple Myeloma
Relapsed-Refractory Multiple Myeloma
Interventions
Drug: Melflufen
Drug: Dexamethasone
Drug: Daratumumab
First Posted Date
2020-12-02
Last Posted Date
2023-06-08
Lead Sponsor
Oncopeptides AB
Target Recruit Count
54
Registration Number
NCT04649060
Locations
🇵🇱

Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department, Kraków, Poland

🇧🇬

Specialized Hospital for Active Treatment of Hematological Diseases, Clinical Hematology Clinic, Sofia, Bulgaria

🇨🇿

University Hospital Hradec Kralove, 4th Internal Clinic of Hematology, Kralovice, Czechia

and more 23 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy